Twist Bioscience Corporation (TWST) 股票分析

公司概述

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products, specifically offering synthetic genes and gene fragments utilized for product development across therapeutics, diagnostics, chemicals, materials, food, agriculture, data storage, and academic research applications. The company operates within the Healthcare sector, specifically in the Diagnostics & Research industry, positioning it as a specialized entity focused on biotechnology innovation and molecular synthesis. Its current market capitalization stands at $3.14B, with an annual revenue of $391.56M and a workforce comprising 979 employees, reflecting a significant operational scale in the biotech landscape. These valuation and revenue figures indicate that Twist Bioscience holds a substantial position in the market, suggesting that investors view the company's synthetic biology capabilities as having considerable commercial potential and established traction within its target industries.

财务健康

Twist Bioscience reported a revenue of $391.56M over the trailing twelve months, yet it recorded a net income of -$76,583,000 and an EBITDA of -$112,748,000, revealing a substantial gap between top-line growth and bottom-line profitability that highlights a heavy cost structure likely driven by high research and development expenditures and operational scaling costs. The company generated free cash flow of -$47,241,876, which indicates that current operations are burning cash, thereby limiting immediate financial flexibility until revenue scales sufficiently to cover fixed costs and capital expenditures. In terms of profitability margins, the gross margin stands at 51.6%, suggesting efficient production of synthetic DNA products, while the operating margin of -31.7% and profit margin of -19.6% demonstrate that high operating expenses are erding a significant portion of gross profits before reaching the bottom line. On the balance sheet, the company holds $197.95M in cash against $113.05M in debt, resulting in a debt-to-equity ratio of 24.79, which suggests a balance sheet that is currently leveraged but maintains a strong cash buffer relative to its obligations. The current ratio is 3.78, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, providing ample room to meet short-term financial obligations without distress. Furthermore, the return on equity is -16.8% and the return on assets is -13.5%, metrics that reveal that the company is currently destroying shareholder value and utilizing its assets inefficiently in terms of generating net earnings, a common characteristic of growth-stage biotech firms before they achieve sustained commercial viability.

估值评估

The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is -27.15, implying that the market is pricing in expected future earnings recovery but currently views the stock as a loss-making entity with negative multiple expansion potential. The price-to-book ratio is 6.87, indicating that the market is assigning a significant premium to the company's book value, reflecting high expectations for the future value of its intellectual property and synthetic biology platform rather than its current tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 8.01 and an EV/EBITDA of -27.07 suggest that the stock is being valued primarily on its revenue generation capabilities and sales growth potential rather than current profitability or cash earnings power. The stock's 52-week trading range spans from a low of $23.30 to a high of $57.88, placing the current market price at a specific point within this volatility band where the asset trades below its recent peak but above its yearly floor. With a beta of 2.21, the stock exhibits high price volatility relative to the broader market, meaning that price movements in TWST are expected to be more than twice as large as movements in the overall market index, introducing significant systematic risk for holders.

Growth & Income

Twist Bioscience demonstrated a revenue growth rate of 16.9% year-over-year, whereas earnings growth is N/A due to ongoing net losses, implying that top-line expansion is outpacing profitability which is typical for capital-intensive biotech companies reinvesting heavily in growth initiatives. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it retains all earnings to fund operations and growth rather than distributing cash to shareholders. The absence of dividend payments combined with the company's strategy of reinvesting capital into research and development aligns with the growth profile of synthetic biology firms that prioritize long-term market capture over immediate income generation. Overall, the company presents a growth-oriented profile characterized by accelerating sales, negative but narrowing earnings, and zero dividend distribution, catering to investors seeking exposure to high-potential biotech innovation rather than current income yield.